Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Castle Biosciences, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | -$0.07 | -$0.07 | -$0.07 |
| Q2 2025 | 7 | -$0.68 | -$0.38 | -$0.53 |
| Q3 2025 | 4 | -$0.53 | -$0.51 | -$0.52 |
| Q4 2025 | 4 | -$0.35 | -$0.34 | -$0.34 |
| Q1 2026 | 3 | -$0.54 | -$0.52 | -$0.52 |
| Q2 2026 | 1 | -$0.40 | -$0.38 | -$0.39 |
| Q3 2026 | 1 | -$0.26 | -$0.25 | -$0.26 |
| Q4 2026 | 1 | -$0.27 | -$0.26 | -$0.27 |
| Q1 2027 | 1 | -$0.39 | -$0.37 | -$0.38 |
| Q2 2027 | 1 | -$0.10 | -$0.10 | -$0.10 |
| Q3 2027 | 1 | $0.08 | $0.08 | $0.08 |
| Q4 2027 | 1 | $0.07 | $0.07 | $0.07 |
Castle Biosciences, Inc. Earnings Date And Information
Castle Biosciences, Inc. last posted its earnings results on Monday, November 3rd, 2025. The company reported $-0.02 earnings per share for the quarter, topping analysts' consensus estimates of $-0.34 by $0.32. The company had revenue of 83.04 M for the quarter and had revenue of 332.07 M for the year. Castle Biosciences, Inc. has generated $1 earnings per share over the last year ($0.62 diluted earnings per share) and currently has a price-to-earnings ratio of -122.03. Castle Biosciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 26th, 2026 based on prior year's report dates.
Castle Biosciences, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/03/2025 | Q3 2025 | -$0.34 | -$0.02 | 0.32 | $71.10 M | $83.04 M |
| 08/04/2025 | Q2 2025 | -$0.51 | $0.16 | 0.67 | $71.45 M | $86.19 M |
| 05/05/2025 | Q1 2025 | -$0.08 | -$0.90 | -0.82 | N/A | $87.99 M |
| 02/27/2025 | Q4 2024 | -$0.04 | $0.34 | 0.38 | N/A | $86.31 M |
| 11/04/2024 | Q3 2024 | -$0.06 | $0.08 | 0.14 | $79.85 M | $85.78 M |
| 08/05/2024 | Q2 2024 | -$0.27 | $0.32 | 0.59 | $69.37 M | $87.00 M |
| 05/02/2024 | Q1 2024 | -$0.37 | -$0.09 | 0.28 | N/A | $72.97 M |
| 02/28/2024 | Q4 2023 | -$0.84 | -$0.10 | 0.74 | N/A | $66.12 M |
| 11/02/2023 | Q3 2023 | -$0.92 | -$0.26 | 0.66 | $48.57 M | $61.49 M |
| 08/02/2023 | Q2 2023 | -$1.01 | -$0.70 | 0.31 | $44.19 M | $50.14 M |
| 05/03/2023 | Q1 2023 | -$0.80 | -$1.10 | -0.3 | $37.41 M | $42.04 M |
| 02/28/2023 | Q4 2022 | -$0.91 | -$0.78 | 0.13 | $37.12 M | $38.34 M |
| 11/02/2022 | Q3 2022 | -$0.70 | -$0.77 | -0.07 | $34.76 M | $37.01 M |
| 08/08/2022 | Q2 2022 | -$0.58 | -$0.06 | 0.52 | $28.37 M | $34.84 M |
| 05/09/2022 | Q1 2022 | -$0.67 | -$0.97 | -0.3 | $25.23 M | $26.85 M |
| 02/28/2022 | Q4 2021 | -$0.43 | -$0.25 | 0.18 | $23.74 M | $25.04 M |
| 11/08/2021 | Q3 2021 | -$0.35 | -$0.47 | -0.12 | $22.97 M | $23.48 M |
| 08/09/2021 | Q2 2021 | -$0.29 | -$0.35 | -0.06 | $19.11 M | $22.76 M |
| 05/10/2021 | Q1 2021 | -$0.22 | -$0.17 | 0.05 | $16.72 M | $22.81 M |
| 03/11/2021 | Q4 2020 | N/A | -$0.23 | N/A | $15.74 M | $17.30 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Castle Biosciences, Inc. Earnings: FAQ's
Castle Biosciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 26th, 2026 based offlast year's report dates.
In the previous quarter, Castle Biosciences, Inc. (:CSTL) reported $-0.02 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.34 by $0.32.
The conference call for Castle Biosciences, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Castle Biosciences, Inc.'s latest earnings report can be read online.
Castle Biosciences, Inc. (:CSTL) has a recorded annual revenue of $332.07 M.
Castle Biosciences, Inc. (:CSTL) has a recorded net income of $18.25 M.Castle Biosciences, Inc. has generated $0.66 earnings per share over the last four quarters.
Castle Biosciences, Inc. (:CSTL) has a price-to-earnings ratio of -122.03 and price/earnings-to-growth ratio is 1.22.